KPV 10mg

KPV (Lys-Pro-Val, CAS 69547-51-9, MW 342.43 Da) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). In preclinical research, KPV has been studied for: inhibition of NF-κB nuclear translocation and downstream pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6, IL-8); direct anti-inflammatory activity in IBD models including colitis, Crohn's disease, and ulcerative colitis; intestinal epithelial barrier restoration; dermal wound healing via keratinocyte migration; and in-vitro antimicrobial activity against pathogens including Candida albicans. Its tiny size (3 amino acids) allows it to enter cells directly and act intracellularly — a key mechanism distinguishing it from many larger immunomodulatory compounds. For research use only.

KPV and BPC-157 address gut inflammation through entirely different mechanisms. KPV works intracellularly via melanocortin receptor-mediated NF-κB suppression — it directly reduces the signalling cascade that produces inflammatory cytokines. BPC-157 works extracellularly via the nitric oxide system, VEGFR2, and FAK-paxillin pathways, with a stronger emphasis on angiogenesis, mucosal protection, and gut-brain axis signalling. KPV is particularly studied in IBD-specific cytokine models; BPC-157 is more focused on gut mucosal healing and systemic gut-brain research. Not for human consumption — for research use only.

Conventional immunosuppressants (steroids, calcineurin inhibitors) broadly suppress immune activity across many cell types and pathways. KPV's proposed mechanism in research models is more selective: it enters cells and directly inhibits NF-κB translocation to the nucleus specifically in inflammatory signalling contexts, without the pattern of global immune suppression seen with steroidal compounds. In cell culture and rodent models, this translates to anti-inflammatory activity at the site of inflammation. These are research findings — not clinical claims — and should not be extrapolated to human therapeutic applications. Not for human consumption — for research use only.

Reconstitution: KPV is a small, highly water-soluble tripeptide. Draw 1–2mL of bacteriostatic water into a clean 31G insulin syringe. Inject slowly into the vial and swirl gently until dissolved. The solution should be clear and colourless. Common concentration: 1mL BAC water = 10mg/mL. Storage: Lyophilised — store at −20°C for up to 24 months. Reconstituted — refrigerate at 2–8°C and use within 28 days. Protect from light.

KPV is legal to purchase in Australia for legitimate laboratory research purposes. It is not listed as a scheduled substance under the Poisons Standard when sold for research use only. Purchasers must be 18+ and confirm research-only use. It is not TGA-approved for human consumption, therapeutic, cosmetic, or veterinary use. Our KPV 10mg is independently verified at 99.2% HPLC purity with full COA documentation. Peptide Warehouse dispatches nationwide from our Melbourne warehouse with Australia Post tracking.

KPV's three-amino-acid structure (MW 342.43 Da) makes it one of the smallest research peptides available. This small size has several research implications: exceptional stability and resistance to peptidase degradation compared to larger peptides; ability to penetrate cellular membranes and reach intracellular targets; rapid dissolution in aqueous solution compatible with a wide range of in-vitro assay conditions; and high purity (99.2%) with excellent batch-to-batch consistency. These properties make it well-suited for intracellular NF-κB pathway research and cell culture models. Not for human consumption — for research use only.

KPV has CAS number 69547-51-9, molecular formula C₁₅H₂₉N₃O₄, and molecular weight 342.43 Da. Its sequence is Lys-Pro-Val — three amino acid residues representing the C-terminal tripeptide of the 13-amino acid parent peptide α-MSH. Identity is confirmed in our batches via mass spectrometry as documented in the COA. Not for human consumption — for research use only.